A Novel Method to Generate and Expand Clinical-Grade, Genetically Modified, Tumor-Infiltrating Lymphocytes

Following the clinical success achieved with the first generation of adoptive cell therapy (ACT) utilizing in vitro expanded tumor-infiltrating lymphocytes (TILs), the second and third generations of TIL ACT are evolving toward the use of genetically modified TIL. TIL therapy generally involves the...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Front Immunol
Autors principals: Forget, Marie-Andrée, Tavera, René J., Haymaker, Cara, Ramachandran, Renjith, Malu, Shuti, Zhang, Minying, Wardell, Seth, Fulbright, Orenthial J., Toth, Chistopher Leroy, Gonzalez, Audrey M., Thorsen, Shawne T., Flores, Esteban, Wahl, Arely, Peng, Weiyi, Amaria, Rodabe N., Hwu, Patrick, Bernatchez, Chantale
Format: Artigo
Idioma:Inglês
Publicat: Frontiers Media S.A. 2017
Matèries:
Immunology
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5539190/
https://ncbi.nlm.nih.gov/pubmed/28824634
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2017.00908
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars